Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 2008 Feb;9(2):210-25



Pubmed ID


Scopus ID

2-s2.0-38849190721   26 Citations


Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the potential treatment of methicillin-resistant Staphylococcus aureus infections, including complicated skin and skin structure infections and hospital-acquired pneumonia. Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing.

Author List

Peppard WJ, Schuenke CD


William J. Peppard PharmD Trauma/Surgical Critical Care Pharmacist in the Pharmacy department at Froedtert Hospital

MESH terms used to index this publication - Major topics in bold

Anti-Bacterial Agents
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Evaluation, Preclinical
Folic Acid Antagonists
Methicillin Resistance
Molecular Structure
Patents as Topic
Staphylococcal Infections
Structure-Activity Relationship
jenkins-FCD Prod-468 69a93cef3257f26b866d455c1d2b2d0f28382f14